Cargando…

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

BACKGROUND: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Bjoern, Luebke, Nadine, Feldt, Torsten, Keitel, Verena, Brandenburger, Timo, Kindgen-Milles, Detlef, Lutterbeck, Matthias, Freise, Noemi F, Schoeler, David, Haas, Rainer, Dilthey, Alexander, Adams, Ortwin, Walker, Andreas, Timm, Joerg, Luedde, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278033/ https://www.ncbi.nlm.nih.gov/pubmed/34278371 http://dx.doi.org/10.1016/j.lanepe.2021.100164

Ejemplares similares

Why the application of IVIG might be beneficial in patients with COVID-19
por: Kindgen-Milles, Detlef, et al.
Publicado: (2022)

Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events, North-Rhine Westphalia, Germany, February and March 2020
por: Walker, Andreas, et al.
Publicado: (2020)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

Gallbladder Wall Thickening associated with Dengue Shock Syndrome in a German traveller – no indication for surgical therapy – a case report
por: Freise, Noemi F., et al.
Publicado: (2021)

Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV)
por: Kindgen-Milles, Detlef, et al.
Publicado: (2021)

Individualisierte Medizin im Zeitalter von Biomarkern und künstlicher Intelligenz
por: Kindgen-Milles, Detlef
Publicado: (2023)

ECMO-Kanülierung bei COVID-19: Venovenöse extrakorporale Membranoxygenierung bei COVID-19: Einfluss der Kanülierungsstrategie auf das Therapieergebnis
por: Immohr, Moritz Benjamin, et al.
Publicado: (2022)

Venovenöse extrakorporale Membranoxygenierung bei COVID-19: Erkenntnisse eines Zentrums aus 96 konsekutiven Fällen
por: Hettlich, Vincent, et al.
Publicado: (2022)

Elimination of fosfomycin during dialysis with the Genius system in septic patients
por: Dimski, T., et al.
Publicado: (2021)

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2021)

Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient
por: Sabin, Arick P., et al.
Publicado: (2022)

Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers
por: Kindgen-Milles, Detlef, et al.
Publicado: (2015)

Prolonged Neuropsychological Deficits, Central Nervous System Involvement, and Brain Stem Affection After COVID-19—A Case Series
por: Groiss, Stefan Jun, et al.
Publicado: (2020)

Secreted Cytokines within the Urine of AKI Patients Modulate TP53 and SIRT1 Levels in a Human Podocyte Cell Model
por: Erichsen, Lars, et al.
Publicado: (2023)

Specialist Palliative Care Consultations in COVID-19 Patients in the ICU—A Retrospective Analysis of Patient Characteristics and Symptoms at a German University Hospital
por: Tenge, Theresa, et al.
Publicado: (2022)

Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19
por: Fischer, Johannes C., et al.
Publicado: (2021)

Secondary sclerosing cholangitis as a complication of severe COVID‐19: A case report and review of the literature
por: Klindt, Caroline, et al.
Publicado: (2021)

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
por: Keitel, Verena, et al.
Publicado: (2021)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption
por: Schneider, Antoine G., et al.
Publicado: (2021)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Émergence de variants E484 K suite à une monothérapie bamlanivimab chez des patients COVID-19 à haut risque d’évolution vers une forme sévère
por: Peiffer-Smadja, N., et al.
Publicado: (2021)

Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis
por: Nierhaus, Axel, et al.
Publicado: (2020)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy
por: Scheier, Joerg, et al.
Publicado: (2022)

Prevalence and prognostic value of neurological affections in hospitalized patients with moderate to severe COVID-19 based on objective assessments
por: Balloff, Carolin, et al.
Publicado: (2023)

Core body temperatures during final stages of life—an evaluation of data from in-hospital decedents
por: Scheidemann, Patrick, et al.
Publicado: (2022)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Super high-flux CVVHD using regional citrate anticoagulation: long-term stability of middle molecule clearance
por: Siebeck, M, et al.
Publicado: (2015)

Akzidentelle Atemkalkingestion im Rahmen eines Tauchganges
por: Michael, Mark, et al.
Publicado: (2021)

Extracellular Vesicles as Markers of Liver Function: Optimized Workflow for Biomarker Identification in Liver Disease
por: Paluschinski, Martha, et al.
Publicado: (2023)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing
por: Fischer, Johannes C., et al.
Publicado: (2021)

Informed consent and informed intervention: SARS-CoV-2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing
por: Fischer, Johannes C., et al.
Publicado: (2021)

Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort
por: Freise, Noemi F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bp7ghl2op7khhfrvl0ke17j56l